Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCORD study of oral runcaciguat in chronic kidney disease with diabetes and/or hypertension and cardiovascular comorbidity
MOH_2020-06-03_008871Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Runcaciguat with Placebo (2 arms). Primary endpoints: Safety, Tolerability and 1 more. Started Mar 2020; status: recruiting.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2020-06-03_008871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-03_008871.